Relacorilant added to nab-paclitaxel prolongs progression-free survival in platinum-resistant ovarian cancer
The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
Experts recommend limiting germline genetic testing for breast cancer to seven genes
Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families
The emerging era of liquid biopsy in endocrine-resistant metastatic breast cancer
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations
First-line use of antibody-drug conjugates: a turning point in metastatic breast cancer
Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending
New evidence is reshaping second-line and maintenance treatment for small cell lung cancer
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival
AI integration in breast cancer – a long way ahead?
Experts’ discussions during ESMO Breast 2025 provided an overview on promises and challenges in the field
Cancer Control Principles
Microplastics and cancer: a microscopic threat, a macro challenge
Evidence is growing for a potential role of microplastics in cancer development, but more solid research is needed
Will voice-enabled AI have a role in oncology?
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Study findings support a growing shift towards “personalised de-escalation” treatment strategies in anal and rectal cancer care
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers